Get access

Safety of rapid rituximab infusion in adult cancer patients: A systematic review

Authors

  • Dora SP Lang RN BSN ADNsg (Oncology),

    Corresponding author
    1. MSc Clinical Science Candidate, Singapore National University Hospital Centre for Evidence Based Nursing, A Joanna Briggs Institute Collaborating Centre, Singapore, The Joanna Briggs Institute, Faculty of Health Sciences, The University of Adelaide, Adelaide, South Australia, Australia
    Search for more papers by this author
  • Christina Hagger BA(Hons) MBA PhD,

    1. Research Fellow, Joanna Briggs Institute, University of Adelaide, Adelaide, South Australia, Australia
    Search for more papers by this author
  • Alan Pearson RN MSc PhD FRCNA FCN FAAG FRCN

    1. Professor, Joanna Briggs Institute, University of Adelaide, Adelaide, South Australia, Australia
    Search for more papers by this author

Dora SP Lang, The Joanna Briggs Institute, Faculty of Health Sciences, The University of Adelaide, Adelaide, SA 5005, Australia. Email: siew.lang@adelaide.edu.au

Abstract

Lang DSP, Hagger C, Pearson A. International Journal of Nursing Practice 2011; 17: 357–369

Safety of rapid rituximab infusion in adult cancer patients: A systematic review

The purpose of this study is to critically appraise, synthesize and present the best available evidence related to the safety of rapid rituximab infusion in adult non-Hodgkin lymphoma and chronic lymphocytic leukaemia patients. Data are from published and unpublished studies from electronic databases, grey literature and reference lists. The studies that met the inclusion criteria were critically appraised by two independent reviewers for methodological validity using standardized critical appraisal instruments. Proportional meta-analysis based on DerSimonian–Laird weights using a random effects model was used for statistical pooling through Stats Direct. Heterogeneity is assessed using Cochran Q. When statistical pooling is not possible, the findings were presented in narrative summary. Rapid rituximab infusion is safe for non-Hodgkin lymphoma patients at a 90 min regimen. However, there is insufficient evidence to support rapid rituximab infusions for chronic lymphocytic leukaemia patients.

Ancillary